Evidence map›Paper›PMID 41192933›Full record

Trial reportBMJ open diabetes research & care2025

Rapid improvements in glycemic management with use of continuous glucose monitoring in adults with type 2 diabetes treated with basal insulin: 3-month analysis of the MOBILE study.

Thomas W Martens, Roy W Beck, Corbin Griffen, Junrui Di, Karen Elkind-Hirsch, Matthew L Johnson, Jessica R Castle, Stayce E Beck, Richard M Bergenstal

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMJ open diabetes research & care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03566693 (Continuous Glucose Monitoring), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03566693 nacompletednot on this map

Continuous Glucose Monitoring (CGM) in Type 2 Diabetes (T2D) Basal Insulin Users: The Mobile Study (MOBILE)

TypeinterventionalSponsorDexCom, Inc.Ran2018 to 2021Enrolled176ConditionsDiabetes Mellitus, Type 2ArmsDexcom G6 CGM System, Blood glucose meter
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Thomas W MartensInternational Diabetes Center, HealthPartners Institute, Bloomington, Minnesota, USA.
Roy W BeckJaeb Center for Health Research, Tampa, Florida, USA rbeck@jaeb.org.
Corbin GriffenDexcom, Inc, San Diego, California, USA.ORCID http://orcid.org/0000-0002-8269-1401
Junrui DiDexcom, Inc, San Diego, California, USA.ORCID http://orcid.org/0000-0001-6325-8090
Karen Elkind-HirschDexcom, Inc, San Diego, California, USA.ORCID http://orcid.org/0000-0003-3577-4009
Matthew L JohnsonDexcom, Inc, San Diego, California, USA.ORCID http://orcid.org/0000-0001-9576-9450
Jessica R CastleDexcom, Inc, San Diego, California, USA.
Stayce E BeckDexcom, Inc, San Diego, California, USA.
Richard M BergenstalInternational Diabetes Center, HealthPartners Institute, Bloomington, Minnesota, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis analysis investigated whether use of real-time continuous glucose monitoring (CGM) compared with blood glucose monitoring (BGM) results in rapidly improved glycemic management in adults with type 2 diabetes (T2D) treated with basal insulin. RESEARCH DESIGN AND

methodsUsing data from the MOBILE study where adults (n=175) with T2D treated with basal insulin without prandial insulin were randomized (2:1) to either CGM (n=116) or BGM (n=59), the treatment effect on glycemic management was determined over 3 months. The main outcome was a between-group difference in hemoglobin A

resultsAfter 3 months, there was a greater reduction from baseline in mean HbA

conclusionsIn adults with basal insulin-treated T2D, use of CGM compared with BGM resulted in rapidly improved glycemic management, with a substantial reduction in HbA TRIAL REGISTRATION NUMBER: NCT03566693.

Indexed as

BiomarkersBlood GlucoseBlood Glucose Self-MonitoringDiabetes Mellitus, Type 2Glycemic ControlHypoglycemiaHypoglycemic AgentsInsulinAdultAgedContinuous Glucose MonitoringFemaleFollow-Up StudiesGlycated HemoglobinHumansMaleBiomarkersBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsInsulinBlood Glucose Self-MonitoringDiabetes Mellitus, Type 2Glycated Hemoglobin A

Identifiers

PMID41192933
PMCPMC12587997

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.